Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: A propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatments.
Saved in:
| Title: | Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: A propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatments. |
|---|---|
| Authors: | Muros-Le Rouzic E; F. Hoffmann-La Roche Ltd., Basel, Switzerland., Heer Y; PricewaterhouseCoopers AG, Zürich, Switzerland., Yiu S; Roche Products Limited, Welwyn Garden City, UK., Tozzi V; PricewaterhouseCoopers AG, Zürich, Switzerland., Braune S; NeuroTransData GmbH, Neuburg an der Donau, Germany., van Hövell P; PricewaterhouseCoopers AG, Zürich, Switzerland., Bergmann A; NeuroTransData GmbH, Neuburg an der Donau, Germany., Bernasconi C; F. Hoffmann-La Roche Ltd., Basel, Switzerland., Model F; F. Hoffmann-La Roche Ltd., Basel, Switzerland., Craveiro L; F. Hoffmann-La Roche Ltd., Basel, Switzerland. |
| Corporate Authors: | NTD study group |
| Source: | Journal of central nervous system disease [J Cent Nerv Syst Dis] 2024 Sep 13; Vol. 16, pp. 11795735241260563. Date of Electronic Publication: 2024 Sep 13 (Print Publication: 2024). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: SAGE Publications Country of Publication: United States NLM ID: 101595026 Publication Model: eCollection Cited Medium: Print ISSN: 1179-5735 (Print) Linking ISSN: 11795735 NLM ISO Abbreviation: J Cent Nerv Syst Dis Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 39290861 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: A propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatments. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Muros-Le+Rouzic+E%22">Muros-Le Rouzic E</searchLink>; F. Hoffmann-La Roche Ltd., Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Heer+Y%22">Heer Y</searchLink>; PricewaterhouseCoopers AG, Zürich, Switzerland.<br /><searchLink fieldCode="AU" term="%22Yiu+S%22">Yiu S</searchLink>; Roche Products Limited, Welwyn Garden City, UK.<br /><searchLink fieldCode="AU" term="%22Tozzi+V%22">Tozzi V</searchLink>; PricewaterhouseCoopers AG, Zürich, Switzerland.<br /><searchLink fieldCode="AU" term="%22Braune+S%22">Braune S</searchLink>; NeuroTransData GmbH, Neuburg an der Donau, Germany.<br /><searchLink fieldCode="AU" term="%22van+Hövell+P%22">van Hövell P</searchLink>; PricewaterhouseCoopers AG, Zürich, Switzerland.<br /><searchLink fieldCode="AU" term="%22Bergmann+A%22">Bergmann A</searchLink>; NeuroTransData GmbH, Neuburg an der Donau, Germany.<br /><searchLink fieldCode="AU" term="%22Bernasconi+C%22">Bernasconi C</searchLink>; F. Hoffmann-La Roche Ltd., Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Model+F%22">Model F</searchLink>; F. Hoffmann-La Roche Ltd., Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Craveiro+L%22">Craveiro L</searchLink>; F. Hoffmann-La Roche Ltd., Basel, Switzerland. – Name: AuthorCorporate Label: Corporate Authors Group: Au Data: <searchLink fieldCode="CA" term="%22NTD+study+group%22">NTD study group</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101595026%22">Journal of central nervous system disease</searchLink> [J Cent Nerv Syst Dis] 2024 Sep 13; Vol. 16, pp. 11795735241260563. <i>Date of Electronic Publication: </i>2024 Sep 13 (<i>Print Publication: </i>2024). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22SAGE+Publications%22">SAGE Publications </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101595026 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>1179-5735 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2211795735%22">11795735 </searchLink><i>NLM ISO Abbreviation: </i>J Cent Nerv Syst Dis <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39290861 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1177/11795735241260563 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 11795735241260563 Titles: – TitleFull: Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: A propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatments. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Muros-Le Rouzic E – PersonEntity: Name: NameFull: Heer Y – PersonEntity: Name: NameFull: Yiu S – PersonEntity: Name: NameFull: Tozzi V – PersonEntity: Name: NameFull: Braune S – PersonEntity: Name: NameFull: van Hövell P – PersonEntity: Name: NameFull: Bergmann A – PersonEntity: Name: NameFull: Bernasconi C – PersonEntity: Name: NameFull: Model F – PersonEntity: Name: NameFull: Craveiro L IsPartOfRelationships: – BibEntity: Dates: – D: 13 M: 09 Text: 2024 Sep 13 Type: published Y: 2024 Identifiers: – Type: issn-print Value: 1179-5735 Numbering: – Type: volume Value: 16 Titles: – TitleFull: Journal of central nervous system disease Type: main |
| ResultId | 1 |
